CN104334532B - 异喹啉和二氮杂萘衍生物 - Google Patents

异喹啉和二氮杂萘衍生物 Download PDF

Info

Publication number
CN104334532B
CN104334532B CN201380013877.8A CN201380013877A CN104334532B CN 104334532 B CN104334532 B CN 104334532B CN 201380013877 A CN201380013877 A CN 201380013877A CN 104334532 B CN104334532 B CN 104334532B
Authority
CN
China
Prior art keywords
alkyl
substituted
heterocyclyl
compound
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380013877.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104334532A (zh
Inventor
陈慧芬
泰利.克劳福德
史蒂芬.R.马格努森
茱蒂.杜巴库
王岚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN104334532A publication Critical patent/CN104334532A/zh
Application granted granted Critical
Publication of CN104334532B publication Critical patent/CN104334532B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN201380013877.8A 2012-01-30 2013-01-29 异喹啉和二氮杂萘衍生物 Expired - Fee Related CN104334532B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261592443P 2012-01-30 2012-01-30
US61/592,443 2012-01-30
US201261593775P 2012-02-01 2012-02-01
US61/593,775 2012-02-01
US201261701916P 2012-09-17 2012-09-17
US61/701,916 2012-09-17
PCT/EP2013/051613 WO2013113669A1 (en) 2012-01-30 2013-01-29 Isoquinoline and naphthyridine derivatives

Publications (2)

Publication Number Publication Date
CN104334532A CN104334532A (zh) 2015-02-04
CN104334532B true CN104334532B (zh) 2018-08-14

Family

ID=47666117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380013877.8A Expired - Fee Related CN104334532B (zh) 2012-01-30 2013-01-29 异喹啉和二氮杂萘衍生物

Country Status (10)

Country Link
US (1) US9586956B2 (https=)
EP (1) EP2809652B1 (https=)
JP (1) JP6363020B2 (https=)
KR (1) KR20140117651A (https=)
CN (1) CN104334532B (https=)
BR (1) BR112014018670A8 (https=)
CA (1) CA2863132A1 (https=)
MX (1) MX353190B (https=)
RU (1) RU2014133390A (https=)
WO (1) WO2013113669A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511237A (ja) * 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 選択的ｈｄａｃ３阻害剤
WO2016114816A1 (en) * 2015-01-18 2016-07-21 Sri International MAP4K4 (HGK) Inhibitors
AU2018347783B2 (en) * 2017-10-13 2023-03-16 Imperial College Innovations Limited MAP4K4 inhibitors
GB201819839D0 (en) 2018-12-05 2019-01-23 Imperial Innovations Ltd MAP4K4 inhibitors
CN110066259A (zh) * 2019-05-22 2019-07-30 南京合巨药业有限公司 一种n-环戊基-1,1-二氧代-4-硫代吗啉甲酰胺的合成方法
CN110028432A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种（3-氨基-氮杂环丁烷-1-基）-环丙基-甲酮的制备方法
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
WO2022150962A1 (en) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
CN117279896A (zh) * 2021-04-07 2023-12-22 劲方医药科技(上海)有限公司 氨基取代的吡啶并环类化合物及其制法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641351A (zh) * 2006-12-21 2010-02-03 普莱希科公司 用于激酶调节的化合物和方法及其适应症
CN101668757A (zh) * 2006-12-21 2010-03-10 普莱希科公司 作为激酶调节剂的吡咯并[2,3-b]吡啶衍生物
WO2010111527A1 (en) * 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
AU776962B2 (en) * 1999-04-21 2004-09-30 Wyeth Holdings Corporation Substituted 3-cyano-(1.7), (1.5), and (1.8)-naphthyridine inhibitors of tyrosine kinases
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641351A (zh) * 2006-12-21 2010-02-03 普莱希科公司 用于激酶调节的化合物和方法及其适应症
CN101668757A (zh) * 2006-12-21 2010-03-10 普莱希科公司 作为激酶调节剂的吡咯并[2,3-b]吡啶衍生物
WO2010111527A1 (en) * 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use

Also Published As

Publication number Publication date
CN104334532A (zh) 2015-02-04
US20140343036A1 (en) 2014-11-20
MX353190B (es) 2018-01-05
EP2809652A1 (en) 2014-12-10
RU2014133390A (ru) 2016-03-20
US9586956B2 (en) 2017-03-07
JP2015509921A (ja) 2015-04-02
WO2013113669A1 (en) 2013-08-08
HK1202291A1 (en) 2015-09-25
BR112014018670A8 (pt) 2017-07-11
MX2014009180A (es) 2014-10-13
BR112014018670A2 (https=) 2017-06-20
JP6363020B2 (ja) 2018-07-25
CA2863132A1 (en) 2013-08-08
KR20140117651A (ko) 2014-10-07
EP2809652B1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
CN104334532B (zh) 异喹啉和二氮杂萘衍生物
CN113382991B (zh) 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN104507933B (zh) 氨基喹唑啉和吡啶并嘧啶衍生物
WO2023051716A1 (zh) 杂芳基衍生物parp抑制剂及其用途
CN114671864B (zh) 杂芳基取代的吡啶及使用方法
CN103974948B (zh) 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑
WO2023217232A1 (zh) 驱动蛋白kif18a抑制剂及其应用
CN101765596B (zh) 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂
TW202214605A (zh) 免疫調節劑、組合物及其方法
MD4212529T2 (ro) Compuși heterociclici ca imunomodulatori
CA3155569A1 (en) Polyheterocyclic modulators of sting (stimulator of interferon genes)
BR112016013632B1 (pt) Carboxamidas, seus usos, seus intermediários e seu processo de preparação, e medicamento
WO2024255782A1 (zh) 双环衍生物parp抑制剂及其用途
CN106573906A (zh) 哌啶‑二酮衍生物
AU2014249003A1 (en) Novel compounds and compositions for inhibition of FASN
CN107849053B (zh) 螺环化合物
BR112017019653B1 (pt) Composto de formula i e composição farmaceutica
CA3256658A1 (en) BICYCLE-DERIVED PARP INHIBITOR AND ITS USE
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
CN115698004A (zh) 作为hpk1抑制剂的氮杂内酰胺化合物
TW201710250A (zh) 經取代之喹喏啉衍生物
WO2025021003A1 (zh) 芳香酰胺类衍生物及其制备方法和用途
CN107849042A (zh) 双环杂环衍生物
WO2023216753A1 (zh) 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途
WO2022007966A1 (zh) Pb2抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202291

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180814

CF01 Termination of patent right due to non-payment of annual fee